May 2022 Special Ariez


On Friday 11 and March 12 2022, the 9th Belgian Multidisciplinary meeting on Urological Cancers took place as a hybrid event with the goal to unite medical oncologists, urologists, radiation oncologists and other colleagues involved in GU oncology.

During the first session of BMUC 2022, Prof. Richard Cathomas provided an overview on the clinical potential of perioperative (neo)adjuvant therapy in the management of bladder cancer.

In the following three keynote lectures, the potential of next-generation imaging techniques was assessed. While Prof. Padhani placed conventional BS/CT scans as still the centre of care for patients with prostate cancer, Dr. Daniela E. Oprea-Lager and Prof. Karolien Goffin focused on the advantages and pitfalls of PSMA-PET in this setting.

To date, the optimal treatment for patients with high-risk, localized PCa remains controversial. While it is important to offer these patients an effective treatment, this treatment should not come with excessive side effects or impact the patient’s quality of life. The different treatment options for these patients were discussed from the perspective of the surgeon, the medical oncologist and the radiation oncologist.

Furthermore, André Deschamps (prostate cancer patient and Chairman of Europa UOMO) discussed the effect of prostate cancer and its treatment on the daily life of patients and addressed some of the barriers and gaps that hamper a closer involvement of patients in the treatment decision process.

The second day of the 2022 annual BMUC meeting kicked off with a session addressing three hot topics in the field of kidney cancer. In a first lecture, Prof. Toni Choueiri discussed the management of patients with non-clear cell renal cell carcinoma (RCC). Subsequently, Dr. Marco Gizzi turned the attention to the adjuvant treatment of patients with RCC after which he gave an overview of new molecules for patients with metastatic RCC. Dr. Stephanie Kroeze closed the RCC session with a presentation on how to combine radiotherapy with systemic therapy in this setting.

Finally, and in line with the tradition, the BMUC scientific committee asked an urologist, a radiation oncologist, and a medical oncologist to summarise the top stories presented during the large urology and oncology meetings of the past year.

We wish you a pleasant read!